Hypoxia inducible factor-1α as a cancer drug target

Molecular Cancer Therapeutics

Volumn 3, Issue 5, 2004, Pages 647-654

  Powis, Garth ^a   Kirkpatrick, Lynn ^b  

^a UNIVERSITY OF ARIZONA   (United States)

^b Biomira Inc   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

1 BENZYL 3 (5 HYDROXYMETHYL 2 FURYL)INDAZOLE; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 METHOXYESTRADIOL; 2 MORPHOLINO 8 PHENYLCHROMONE; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPHENYLIODONIUM SALT; DNA TOPOISOMERASE INHIBITOR; FLAVONOID; FR 901228; GELDANAMYCIN; GENISTEIN; GL 331; HISTONE DEACETYLASE INHIBITOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; KF 58333; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PACLITAXEL; PROTEIN KINASE INHIBITOR; PX 12; PX 478; RADICICOL; RAPAMYCIN; TOPOTECAN; TRANSCRIPTION FACTOR; UCNO 1; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; VINCRISTINE; WORTMANNIN;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; CANCER CELL CULTURE; CANCER GROWTH; CANCER PATIENT; CELL SURVIVAL; CORRELATION ANALYSIS; DRUG CYTOTOXICITY; DRUG DNA BINDING; DRUG MECHANISM; DRUG TARGETING; ENZYME INHIBITION; GENE ACTIVATION; GENE INACTIVATION; HUMAN; IN VIVO STUDY; NONHUMAN; ONCOGENE; OXIDATION REDUCTION REACTION; PRIORITY JOURNAL; PROGNOSIS; RNA TRANSLATION; SHORT SURVEY; TRANSACTIVATION; TRANSCRIPTION REGULATION; TUMOR GROWTH; TUMOR SUPPRESSOR GENE;

ANTINEOPLASTIC AGENTS; CELL HYPOXIA; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; NEOPLASMS; SIGNAL TRANSDUCTION; TRANS-ACTIVATION (GENETICS); TRANSCRIPTION FACTORS;

EID: 4444311880     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (61)

1. Harris AL. Hypoxia - a key regulatory factor in tumour growth. Nat Rev 2002;2:38-47.
2. Semenza GL. HIF-1 and tumor progression: pathophysiology and therapeutics. Trends Mol Med 2002;8:S62-7.
3. Maxwell PH, Pugh CW, Ratcliffe PJ. The pVHL-HIF-1 system. A key mediator of oxygen homeostasis. Adv Exp Med Biol 2001;502:365-76.
4. Ravi R, Mookerjee B, Bhujwalla Z, et al. Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1α. Genes Dev 2000;14:34-44.
5. Gradin K, McGuire J, Wenger RH, et al. Functional interference between hypoxia and dioxin signal transduction pathways: competition for recruitment of the Arnt transcription factor. Mol Cell Biol 1996;16: 5221-31.
6. Isaacs JS, Jung YJ, Mimnaugh EG, Martinez A, Cuttitta F, Neckers LM. Hsp90 regulates a von Hippel Lindau-independent hypoxia-inducible factor-1α-degradative pathway. J Biol Chem 2002;277:29936-44.
7. Jiang BH, Jiang G, Zheng JZ, Hunter T, Vogt PK. Phosphatidylinositol 3-kinase signaling controls levels of hypoxia-inducible factor 1. Cell Growth & Differ 2001;12:363-9.
8. Hudson CC, Liu M, Chiang GG, et al. Regulation of hypoxia-inducible factor 1α expression and function by the mammalian target of rapamycin. Mol Cell Biol 2002;22:7004-14.
9. Alvarez-Tejado M, Naranjo-Suarez S, Jimenez C, Carrara AC, Landzuri MO, del Peso L. Hypoxia induces the activation of the phosphatidylinositol-3-kinase/AKT cell survival pathway in PC12 cells. Protective role in apoptosis. J Biol Chem 2001;276:22368-74.
10. Kallio PJ, Okamoto K, O'Brian S, et al. Signal transduction in hypoxic cells: inducible nuclear translocation and recruitment of the CBP/p300 coactivator by the hypoxia inducible factor-1α. EMBO J 1998;17: 6573-86.
11. Jiang BH, Rue E, Wang GI, Roe R, Semenza GL. Dimerization, DNA binding and transactivation properties of hypoxia-inducible factor-1 . J Biol Chem 1996;271:17771-8.
12. Pugh CW, O'Rourke JF, Nagao M, Gleadle J, Ratcliffe PJ. Activation of hypoxia-inducible factor-1; definition of regulatory domains within the α subunit. J Biol Chem 1997;272:11205-14.
13. Sang N, Stiehl DP, Bohensky J, Leshchinsky I, Srivnas V, Caro J. MAPK signaling up-regulates the activity of hypoxia-inducible factors by its effects on p300. J Biol Chem 2003;278:14013-9.
14. Zundel W, Schindler C, Haas-Kogan D, et al. Loss of PTEN facilitates HIF-1-mediated gene expression. Genes Dev 2000;14:391-6.
15. Srinivas V, Zhu X, Salceda S, Nakamura R, Caro J. Hypoxia-inducible factor 1α (HIF-1α) is a non-hemeiron protein. Implications for oxygen sensing. J Biol Chem 1998;273:18019-22.
16. Welsh SJ, Bellamy WT, Briehl MM, Powis G. The redox protein thioredoxin-1 (Trx-1) increases hypoxia-inducible factor 1α protein expression: Trx-1 overexpression results in increased vascular endothelial growth factor production and enhanced tumor angiogenesis. Cancer Res 2002;62:5089-95.
17. Ema M, Hirota K, Mimura J, et al. Molecular mechanisms of transcription activation by HLF and HIF1α in response to hypoxia: their stabilization and redox signal-induced interaction with CBP/p300. EMBO J 1999;18:1905-14.
18. Talks KL, Turley H, Gatter KC, et al. The expression and distribution of the hypoxia-inducible factors HIF-1α and HIF-2α in normal human tissues, cancers, and tumor-associated macrophages. Am J Pathol 2000;157: 411-21.
19. Zhong H, De Marco A, Laughner E, et al. Over-expression of hypoxia-inducible factor 1α in common human cancers and metastases. Cancer Res 1999;59:5830-5.
20. Giatromanolaki A, Koukourakis M, Sivridis E, Turley H, Talks K. Relation of hypoxia inducible factor 1α and 2α in operable non-small cell lung cancer to angiogenic molecular profile of tumors and survival. Br J Cancer 2001;85:881-90.
21. Birner P, Schindl M, Obermair A, Breitenecker G, Oberhuber G. Expression of hypoxia-inducible factor-1α in epithelial ovarian tumors: its impact on prognosis and on response to chemotherapy. Clin Cancer Res 2001;7:1661-8.
22. Bos R, van der Groep P, Greijer AE, et al. Levels of hypoxia-inducible factor-1α independently predict prognosis in patients with lymph node negative breast carcinoma. Cancer 2003; 97:1573-81.
23. Aebersold DM, Burri P, Beer KT, et al. Expression of hypoxia-inducible factor-1α: a novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer. Cancer Res 2001; 61:2911-6.
24. Bos R, Zhong H, Hanrahan C, et al. Levels of hypoxia-inducible factor-1α during breast carcinogenesis. J Natl Cancer Inst 2001;91:309-14.
25. Zagzag D, Zhong H, Scalzetti J, Laughner E, Simons J, Semenza G. Expression of hypoxia-inducible factor-1α in brain tumors: association with angiogenesis, invasion and progression. Cancer 2000;88:2606-18.
26. Neufeld G, Kessler O, Vadasz Z, Gluzman-Poltorak Z. The contribution of proangiogenic factors to the progression of malignant disease: role of vascular endothelial growth factor and its receptors. Surg Oncol Clin N Am 2001;10:339-56.
27. Pietsch T, Valter MM, Wolf HK, et al. Expression and distribution of vascular endothelial growth factor protein in human brain tumors. Acta Neuropathol 1997;93:109-17.
28. Krieg M, Haas R, Brauch H, Acker T, Flamme I, Plate K. Up-regulation of hypoxia-inducible factors HIF-1α and HIF-2α under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function. Oncogene 2000;19:5435-43.
29. Volm M, Koomagi R. Hypoxia-inducible factor (HIF-1) and its relationship to apoptosis and proliferation in lung cancer. Anticancer Res 2000;20:1527-33.
30. Carmeliet P, Dor Y, Herbert JM, et al. Role of HIF-1α in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature 1998;394:485-90.
31. Bruick RK. Expression of the gene encoding the proapoptotic Nip3 protein is induced by hypoxia. Proc Natl Acad Sci USA 2000;97:9082-7.
32. Koukourakis M, Giatromanolaki A, Skarlatos J, et al. Hypoxia inducible factor (HIF-1α and HIF-2α) expression in early esophageal cancer and response to photodynamic therapy and radiotherapy. Cancer Res 2001;61:1830-2.
33. Sowter HM, Ratcliffe PJ, Watson P, Greenberg AH, Harris AL. HIF-1-dependent regulation of hypoxic induction of the cell death factors BNIP3 and NIX in human tumors. Cancer Res 2001;61:6669-73.
34. Turner KJ, Moore JW, Jones A, et al. Expression of hypoxia-inducible factors in human renal cancer: relationship to angiogenesis and to the von Hippel-Lindau gene mutation. Cancer Res 2002;62:2957-61.
35. Park S, Dadak AM, Haase VH, Fontana L, Giaccia AJ, Johnson RS. Hypoxia-induced gene expression occurs solely through the action of hypoxia-inducible factor 1α (HIF-1α): role of cytoplasmic trapping of HIF-2α. Mol Cell Biol 2003;23:4959-71.
36. Brusselmans K, Bono F, Maxwell Y, et al. Hypoxia-inducible factor-2α (HIF-2α) is involved in the apoptotic response to hypoglycemia but not to hypoxia. J Biol Chem 2001;276:39192-6.
37. Sun X, Kanwar JR, Leung E, Lehnert K, Wang D, Krissansen GW. Gene transfer of antisense hypoxia inducible factor-1α enhances the therapeutic efficacy of cancer immunotherapy. Gene Ther 2001;8:638-45.
38. Welsh SJ, Powis G. Hypoxia inducible factor as a cancer drug target. Curr Cancer Drug Targets 2003;3:391-405.
39. Hur E, Kim HH, Chol SM, et al. Reduction of hypoxia-induced transcription through the repression of hypoxia-inducible factor-1α /Aryl hydrocarbon receptor nuclear translocator DNA binding by the 90-kDa heat-shock protein inhibitor radicicol. Mol Pharmacol 2002;62:975-82.
40. Kurebayashi J, Otsuki T, Kurosumi M, Soga S, Akinaga S, Sonoo H. A radicicol derivative, KF58333, inhibits expression of hypoxia-inducible factor-1α and vascular endothelial growth factor, angiogenesis and growth of human breast cancer xenografts. Jpn J Cancer Res 2001; 92:1342-51.
41. Mabjeesh NJ, Post DE, Willard MT, et al. Geldanamycin induces degradation of hypoxia-inducible factor 1α protein via the proteosome pathway in prostate cancer cells. Cancer Res 2002;62:2478-82.
42. Mabjeesh NJ, Escuin D, LaVallee TM, et al. 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF. Cancer Cell 2003;3:363-75.
43. Jung YJ, Isaacs JS, Lee S, Trepel J, Neckers L. Microtubule disruption utilizes an NF-κB-dependent pathway to stabilize HIF-1α protein. J Biol Chem 2003;278:7445-52.
44. Rapisarda A, Uranchimeg B, Scudiero DA, et al. Identification of small molecule inhibitors of hypoxia-inducible factor 1 transcriptional activation pathway. Cancer Res 2002;62:4316-24.
45. Rapisarda A, Uranchimerg B, Sordet O, Pommier Y, Shoemaker RH, Melillo G. Topoisomerase I-mediated inhibition of hypoxia-inducible factor 1: mechanism and therapeutic implications. Cancer Res 2004;64: 1475-82.
46. Chang H, Shyu KG, Lee CC, et al. GL331 inhibits HIF-1α expression in a lung cancer model. Biochem Biophys Res Commun 2003;302:95-100.
47. Lee YM, Kim SH, Kim HS, et al. Inhibition of hypoxia-induced angiogenesis by FK228, a specific histone deacetylase inhibitor, via suppression of HIF-1α activity. Biochem Biophys Res Commun 2003; 300:241-6.
48. Zhong H, Chiles K, Feldser D, et al. Modulation of hypoxia-inducible factor 1α expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res 2000; 60:1541-5.
49. Laughner E, Taghavi P, Chiles K, Mahon PC, Semenza GL. HER2(neu) signaling increases the rate of hypoxia-inducible factor 1α(HIF-1α) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol Cell Biol 2001; 21:3995-4004.
50. Agani F, Semenza GL. Mersalyl is a novel inducer of vascular endothelial growth factor gene expression and hypoxia-inducible factor 1 activity. Mol Pharmacol 1998;54:749-54.
51. Conrad PW, Freeman TL, Beitner-Johnson D, Millhorn DE. EPAS1 trans-activation during hypoxia requires p42/p44 MAPK. J Biol Chem 1999;274:33709-13.
52. Chun YS, Yeo EJ, Choi E, et al. Inhibitory effect of YC-1 on the hypoxic induction of erythropoietin and vascular endothelial growth factor in Hep3B cells. Biochem Pharmacol 2000;61:947-54.
53. Yeo EJ, Chun YS, Cho YS, et al. YC-1: a potential anticancer drug targeting hypoxia-inducible factor 1. J Natl Cancer Inst 2003;95: 516-25.
54. Welsh SJ, Williams RR, Birmingham A, Newman DJ, Kirkpatrick DL, Powis G. The thioredoxin redox inhibitors 1-methylpropyl 2-imidazolyl disulfide and pleurotin inhibit hypoxia-induced factor 1α and vascular endothelial growth factor formation. Mol Cancer Ther 2003; 2:235-43.
55. Welsh SJ, Williams R, Kirkpatrick L, Paine-Murrieta G, Powis G. Antitumor activity and pharmacodynamic properties of PX-478, an inhibitor of hypoxia inducible factor-1α. Mol Cancer Ther 2004;3: 233-44.
56. Wang GL, Jiang BH, Semenza GL. Effect of protein kinase and phosphatase inhibitors on expression of hypoxia-inducible factor 1. Biochem Biophys Res Commun 1995;216:669-75.
57. Hur E, Chang KY, Lee E, Lee SK, Park H. Mitogen-activated protein kinase kinase inhibitor PD98059 blocks the trans-activation but not the stabilization or DNA binding ability of hypoxia-inducible factor-1α. Mol Pharmacol 2001;59:1216-24.
58. Blancher C, Moore JW, Robertson N, Harris AL. Effects of ras and von Hippel-Lindau (VHL) gene mutations on hypoxia-inducible factor (HIF)-1α, HIF-2α, and vascular endothelial growth factor expression and their regulation by the phosphatidylinositol 3′ -kinase/Akt signaling pathway. Cancer Res 2001;61:7349-55.
59. Kruger EA, Blagoskionny MV, Dixon SC, Figg WD. UCN-01, a protein kinase C inhibitor, inhibits endothelial cell proliferation and angiogenic hypoxic response. Invasion Metastasis 1999;18:209-18.
60. Gleadle JM, Ebert BL, Ratcliffe PJ. Diphenylene iodonium inhibits the induction of erythropoietin and other mammalian genes by hypoxia. Implications for the mechanism of oxygen sensing. Eur J Biochem 1995; 234:92-9.
61. Oliver VK, Patton AM, Desai S, Lorang D, Libutti SK, Kohn EC. Regulation of the pro-angiogenic microenvironment by carboxyamidotriazole. J Cell Physiol 2003;197:139-48.